Bioanalytical Systems, Inc.  

(Public, NASDAQ:BASI)   Watch this stock  
Find more results for Connie Johnson�
+0.03 (1.58%)
Real-time:   10:51AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.93 - 2.02
52 week 1.87 - 2.99
Open 2.02
Vol / Avg. 3,896.00/9,335.00
Mkt cap 15.98M
P/E     -
Div/yield     -
EPS -0.04
Shares 8.08M
Beta 3.03
Inst. own 8%
Feb 12, 2015
Q1 2015 Bioanalytical Systems Inc Earnings Call
Feb 12, 2015
Q1 2015 Bioanalytical Systems Inc Earnings Release
Jan 20, 2015
Bioanalytical Systems Inc at Noble Financial Equity Conference
Dec 22, 2014
Q4 2014 Bioanalytical Systems Inc Earnings Call
Dec 22, 2014
Q4 2014 Bioanalytical Systems Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 3.11% -4.35%
Operating margin 2.43% 1.36%
EBITD margin - 9.38%
Return on average assets 3.07% -4.33%
Return on average equity 8.62% -12.99%
Employees 150 -
CDP Score - -


2701 Kent Avenue, West Lafayett
United States - Map
+1-317-4634527 (Phone)
+1-765-7426699 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Bioanalytical Systems, Inc. is an international contract research organization providing drug discovery and development services and analytical instruments. The Company's clients and partners include pharmaceutical, biotechnology, academic and government organizations. The Company derives its revenues from sales of its research services and drug development tools. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and biomolecule drug candidates. The Company's principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the global pharmaceutical companies. The Company operates in two business segments: contract research services and research products, both of which addresses the bioanalytical, preclinical, and clinical research needs of drug developers.

Officers and directors

John B. Landis Ph.D. Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Jacqueline M. Lemke President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Jeffrey Potrzebowski CPA Chief Financial Officer, Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
James S. Bourdage Ph.D. Vice President - Bioanalytical Operations
Bio & Compensation  - Reuters
John P. Devine Jr. Vice President - Non-Clinical Services
Age: 52
Bio & Compensation  - Reuters
Connie Dougherty Vice President - Business Development
Bio & Compensation  - Reuters
Merrill R. Osheroff Ph.D. Director
Age: 59
Bio & Compensation  - Reuters
Larry S. Boulet Independent Director
Age: 67
Bio & Compensation  - Reuters
Richard A. Johnson Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
David L. Omachinski CPA Independent Director
Age: 62
Bio & Compensation  - Reuters